Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

7 evidence topics · 6 sources

Preclinical solubility, oral bioavailability, and half-life
PropertyRinzimetostat
Solubility“11.7 mg/ml”
Mouse oral bioavailability“64%”
Mouse half-life, oral“3-5 hr PO”
Mouse half-life, intravenous“2.5 hr IV”
Clinical half-life“~20 hrs”